The concomitant use of regorafenib and navitoclax, an inhibitor of Bcl2 family members, showed a synergistic anti-tumor effect both in vitro and in xenograft tumor models established by injecting stable glioma cell lines or glioma stem-like cells. Here, BCL2 is linked to central nervous system cancer.